Journal Supplement to Asia–Pacific Journal ofClinical Oncology

CME INFORMATION

Activity description

There is a significant unmet need for education on breastcancer in the Asia–Pacific region, including basic knowl-edge and information on screening methods, diagnostictechniques, proper management, and the availability ofnovel treatments. Recently, a panel of leading experts inbreast cancer from the Asia–Pacific region met to discussthe epidemiology and management of this disease. Theyagreed that there is limited information in the publishedliterature regarding the prevalence, diagnosis, pathol-ogy, and treatment of breast cancer in the Asia–Pacificregion. Education regarding novel treatment strategiesfor locally advanced and late-stage or metastatic diseaseis particularly important because the majority of Asianpatients with breast cancer continue to be diagnosedwhen their cancer is at a relatively late stage, and locallyadvanced cancers are seen in more than 50% of allpatients diagnosed and managed. This journal supple-ment provides timely and much-needed informationfrom experts in the Asia–Pacific region on the manage-ment of breast cancer and the role of the epothilones inovercoming taxane-resistant and triple-negative disease.

Target audience

This educational activity has been designed to meet theneeds of oncologists and other healthcare providers inthe Asia–Pacific region who treat patients with locallyadvanced metastatic breast cancer.

Learning objectives

At the conclusion of this activity, participants should beable to:• Discuss the limitations of currently available antimi-

crotubule agents in the treatment of patients withmetastatic and locally advanced breast cancer

• Describe the potential role of novel microtubule-stabilizing agents in circumventing the developmentof multidrug resistance

• Summarize the mechanism of action and pharmaco-logic profiles of the different microtubule-stabilizingagents

• Review reported phase II and emerging phase III clini-cal trial results of the epothilones in patients withmetastatic or locally advanced breast cancer, includ-ing patients with triple-negative disease, as well as thepotential use of these new agents as neoadjuvanttherapy

• List emerging novel microtubule-stabilizing agents inearly clinical development

• Summarize the potential clinical applications of theepothilones in combination therapy regimens basedon preclinical and early clinical study results

Accreditation

This activity has been planned and implemented inaccordance with the Essential Areas and Policies of theAccreditation Council for Continuing Medical Educa-tion (ACCME) through the joint sponsorship of theUniversity of Wisconsin School of Medicine and PublicHealth and MDG Development Group. The Universityof Wisconsin School of Medicine and Public Health isaccredited by the ACCME to provide continuingmedical education for physicians.

Credit designation

The University of Wisconsin School of Medicine andPublic Health designates this educational activity for amaximum of 2.0 AMA PRA Category 1 Credits™. Phy-sicians should only claim credit commensurate with theextent of their participation in the activity.

Policy on faculty and sponsor disclosure

As a sponsor accredited by the ACCME, it is the policyof the University of Wisconsin School of Medicine andPublic Health to require the disclosure of the existenceof any significant financial interest or any other relation-ship a faculty member or sponsor has with either thecommercial supporter of this activity or the manufac-turer of any commercial products discussed in an edu-cational presentation. The faculty and sponsor reportedthe following:

MDG Development Group has disclosed thefollowing:• Has a client/provider relationship with Bristol-Myers

Squibb Company

Asia–Pacific Journal of Clinical Oncology 2008; 4(Suppl. 3): S1–S2 doi:10.1111/j.1743-7563.2008.00189.x

© 2008 The AuthorsJournal Compilation © Blackwell Publishing Asia Pty Ltd

Alex Yuang-Chi Chang, MDCEO and Medical DirectorJohns Hopkins Singapore International Medical CentreSingapore• Has acted as a speaker for AstraZeneca, Bristol-

Myers Squibb Company, and Pfizer, Inc.• Has received honoraria from AstraZeneca, Bristol-

Myers Squibb Company, and Pfizer, Inc.Shin-Cheh Chen, MDChief, Breast Surgery DivisionDirector, Breast Cancer TreatmentChang Gung Memorial HospitalTaipei, Taiwan• Has no relevant financial relationship with any com-

mercial interests to discloseLouis W.C. Chow, MDMedical Director of the Comprehensive Centre forBreast DiseasesUNIMED Medical InstituteUniversity of Hong Kong Medical CentreHong Kong, China• Has no relevant financial relationship with any com-

mercial interests to discloseMonica N. Fornier, MDAssistant MemberMemorial Sloan Kettering Cancer CenterNew York, New York, USA• Has acted as a speaker for Bristol-Myers Squibb

Company• Has received honoraria from Bristol-Myers Squibb

CompanyMichael Green, MBBS, FRACP, FAPCAssociate ProfessorRoyal Melbourne HospitalsUniversity of MelbourneVictoria, Australia• Has no relevant financial relationship with any com-

mercial interests to discloseYoung-Hyuck Im, MDAssociate Professor of MedicineSamsung Medical CentreSeoul, Korea• Has no relevant financial relationship with any com-

mercial interests to discloseShinji Ohno, MDHead, Breast Cancer OncologyNational Kyushu Cancer CenterFukuoka, Japan• Has no relevant financial relationship with any com-

mercial interests to disclose

Vinod Raina, MD, FRCPProfessor & Head, Department of Medical OncologyInstitute Rotary Cancer HospitalAll India Institute of Medical SciencesNew Delhi, India• Has no relevant financial relationship with any com-

mercial interests to discloseBinghe Xu, MDProfessor and Director, Division of Breast CancerDepartment of Medical Oncology Cancer HospitalChinese Academy of Medical SciencesBeijing, China• Has no relevant financial relationship with any com-

mercial interests to discloseNotice: The University of Wisconsin School of Medicineand Public Health advises the participant that one ormore presentations in this continuing medical educationactivity may contain reference(s) to unlabeled or unap-proved uses of drugs or devices.

Prerequisites

There are no prerequisites required for participation inthis educational activity. The expected length of time tocomplete this activity is 2 hours.

CME MEDICAL REVIEWER

Toby C. Campbell, MD, MSCIAssistant ProfessorMedical Oncology and Palliative MedicineUniversity of Wisconsin Comprehensive Cancer CenterUniversity of Wisconsin School of Medicine and PublicHealthMadison, Wisconsin, USA• Has no relevant financial relationship with any com-

mercial interests to disclose

Acknowledgement

The University of Wisconsin School of Medicine andPublic Health and MDG Development Group gratefullyacknowledge the independent educational grant pro-vided by Bristol-Myers Squibb Company.Release Date: December 2008Expiration Date: December 2009

S2 CME Information

© 2008 The AuthorsJournal Compilation © Blackwell Publishing Asia Pty Ltd

Asia–Pac J Clin Oncol 2008; 4(Suppl. 3): S1–S2